Belgium· BE-AMP-SAM140962-00

Medialipide 20 %

A fettemulsionen product containing triglycerides medium chain, registered in Belgium by B. Braun Melsungen. The same ATC class is registered in 11 of our 19 countries.

ATC B05BA02

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedMedialipide 20 %ATCB05BA02REGISTER NO.BE-AMP-SAM140962-00PACKS LISTED6CHECKEDSeptember 26, 2026

Where it is registered

Fettemulsionen is registered in 11 of 19 countries.

Countries holding a registration under ATC B05BA02 (fettemulsionen), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose

Fettemulsionen · ATC B05BA02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Triglycerides Medium Chain
Manufacturer
B. Braun Melsungen
Country
Belgium (BE)
ATC code
B05BA02
ATC class
Fettemulsionen
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 6

  • be_apb
    0732636
  • be_apb
    0669580
  • be_apb
    0669606
  • be_apb
    0732610
  • be_apb
    0732628
  • be_apb
    0669598

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Fettemulsionen in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fettemulsionen products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/84e35258-54c2-41e7-8aa9-e0fc147fe3ba
GET /v1/drugs/84e35258-54c2-41e7-8aa9-e0fc147fe3ba?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Emulsion for injection",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Medialipide 20 %",
  "name_fr": "Medialipide 20 %",
  "name_nl": "Medialipide 20 %",
  "amp_code": "SAM140962-00",
  "strengths": [
    "100.0000",
    "100.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Triglycerides Medium Chain",
    "Soya Oil"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Fat Emulsions",
  "authorisation_numbers": [
    "BE141102",
    "BE141111"
  ]
}

See everything about fettemulsionen.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.